Announced Wed, 28 Oct, 2026 · 20:59 IST
September quarter revenue rises 46%, net profit jumps 249%; stamp duty dispute adds risk
Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults RestatedExceptional ItemContingent Liabilities IncreasedResults View source PDFExplain this filing
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction
Awaiting price reaction for this filing.
AI summary
Q2 FY27 consolidated revenue rose 46% year on year to Rs610.45 crore and net profit rose 249% to Rs71.47 crore. H1 revenue rose 42% to Rs1,146.25 crore and net profit rose 122% to Rs147.61 crore. Auditors highlighted a Rs25 crore stamp duty plus Rs34.50 crore penalties. The company booked Rs2.04 crore, is challenging the order, and reports Rs57.46 crore as a possible liability. Prior figures were restated for a forward-contract loss.
Likely market impact
Results support sentiment, but the disputed Rs57.46 crore exposure and working-capital use may cap gains. H1 operating cash flow stayed positive.